Clinical trials: Acne, Adult
Acne Vulgaris
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for moderate to severe…
- Trial name
- NCT05080764
- Testing
- 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Biofrontera Inc.
Hidradenitis Suppurativa
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week…
- Trial name
- SUNRISE (NCT03713632)
- Testing
- Secukinumab
- Where
- 108 sites in United States, Argentina and 30 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week…
- Trial name
- SUNSHINE (NCT03713619)
- Testing
- secukinumab
- Where
- 111 sites in United States, Argentina and 27 more
- Volunteers
- 544 people
- Sponsor
- Novartis Pharmaceuticals
Acne Vulgaris
A Study of the Safety, Engraftment, and Action of Multi-Dosed NB01 in Adults With Moderate Acne
Acne vulgaris is a disease caused my multiple factors including overgrowth of bacteria, clogged pores, excessive sebum production and hormonal changes.
- Trial name
- NCT03709654
- Testing
- NB01, Vehicle Control
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Naked Biome, Inc.
Intracranial Pressure Increase
Ocular Screening in Children and Young Adults at Risk for Increased Intracranial Pressure
The purpose of this study is to evaluate the vision and posterior segment of eyes in children and young adults less than 22 years of age with risk, suspicion, or past medical history significant for elevated intracranial pressure…
- Trial name
- ICP (NCT03286426)
- Testing
- Pictor
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Duke University
Acne Vulgaris
A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne
Acne vulgaris is a multifactorial disease caused by overgrowth of Propionibacterium acnes (P. acnes), impaction of hair follicles, excessive sebum production and hormonal dysregulation.
- Trial name
- NCT03450369
- Testing
- NB01
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Naked Biome, Inc.
Acne Vulgaris
Evaluation of Efficacy and Tolerance of Crystal Peel in the Treatment of Adults Presenting Facial Mild Acne
The goal of this interventional, confirmatory and post market study is to evaluate the efficacy and clinical performance of Crystal Peel in adults suffering mild facial acne vulgaris.
- Trial name
- NCT05821296
- Testing
- Crystal Peel
- Where
- Poland
- Volunteers
- 42 people
- Sponsor
- Dermosciences France
Acne Inversa
A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa
This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks.
- Trial name
- NCT04092452
- Testing
- PF-06650833, PF-06700841, PF-06826647
- Where
- 77 sites in United States, Australia and 1 more
- Volunteers
- 194 people
- Sponsor
- Pfizer
Acne Vulgaris
Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne
An exploratory Phase 2, single, centre, prospective, randomized, placebo-controlled, double-blinded, split-pace (left/right) design trial to evaluate the efficacy and tolerability of LEO 43204 in adults with moderate to severe…
- Trial name
- NCT02575950
- Testing
- LEO43204
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- LEO Pharma